Department of Internal Medicine, University of Maryland Medical Center, Baltimore, MD 21201, USA.
King's College, London, WC2R 2LS, UK.
Future Microbiol. 2024 Sep;19(13):1177-1184. doi: 10.1080/17460913.2024.2363728. Epub 2024 Aug 6.
Infectious diseases lead to significant morbidity and mortality. Often, resolution of the acute stage of the disease leads to microbial persistence, resulting in chronic debilitating disease. Management of persistent infections frequently requires lifelong therapy with antimicrobial agents. These infections could be chronic viral infections like HIV, hepatitis B or chronic bacterial persistent infections like prosthetic joint infections caused by multi-drug resistant organisms. Bacteriophages have been designed specifically to target recalcitrant bacterial infections, such as prosthetic joint infections with varying success. In this review, we describe the historic evolution of scenarios and risks associated with innovative therapy using infectious agents to treat other persistent infections.
传染病可导致严重的发病率和死亡率。通常，急性疾病阶段的消退会导致微生物持续存在，从而导致慢性衰弱性疾病。持续性感染的治疗通常需要长期使用抗菌药物。这些感染可能是慢性病毒感染，如 HIV、乙型肝炎，也可能是慢性细菌持续性感染，如由多药耐药菌引起的人工关节感染。噬菌体是专门设计来靶向难治性细菌感染的，如人工关节感染，其成功率各不相同。在这篇综述中，我们描述了使用感染性制剂治疗其他持续性感染的创新疗法相关的历史演变情况和风险。
